Biogen Inc. (BIIB) stock rallied over 3.28% intraday to trade at $210.63 a share on NASDAQ. The stock opened with a gain of 3.46% at $205.37 and touched an intraday high of $210.75, rising 3.28% against the last close of $203.94. The stock went to a low of $203.92 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue10.98 Billion
5Y Sales Change-0.80%
Fiscal Year Ends2021-12-30
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Biogen Inc. (NASDAQ: BIIB) stock price is $210.63 as of the last check on Friday, July 1. During the trading session, BIIB stock reached the peak price of $210.75 while $203.92 was the lowest point it dropped to.
The NASDAQ listed BIIB is part of Biotechnology industry that operates in the broader Health Care sector. Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases.
Mr. Chirfi Guindo
Exec. VP of Global Product Strategy & Commercialization
Dr. Alphonse Galdes
Exec. VP of Pharmaceutical Operations & Technology
Dr. Anabella Villalobos Ph.D.
Sr. VP of Biotherapeutic & Medicinal Sciences
Mr. Michel Vounatsos
CEO & Director
BIIB stock traded closed the last session at $210.63, which is $6.69 or 3.28% lower than its previous close of $203.94. BIIB's current trading price is 12.54% lower than its 52-week high of $372.11 where as its distance from 52-week low of 187.16% is -43.40%.
Number of BIIB employees currently stands at -. BIIB operates from 225 Binney Street, Cambridge, MA 02142, United States.
Official Webiste of $BIIB is: https://www.biogen.com
BIIB stock volume for the day was 800,698 shares while in the previous session number of BIIB shares traded was 800,700 . The average number of BIIB shares traded daily for last 3 months was 1.14 Million.
The percentage change in BIIB stock occurred in the recent session was 3.28% while the dollar amount for the price change in BIIB stock was $6.69.
In the recent session, the day high for BIIB stock was $210.75 while the low for BIIB stock touched on the day was $203.92.
The market value of BIIB currently stands at 29.87 Billion with its latest stock price at $210.63 and 147.1 Million of its shares outstanding.